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The Epstein–Barr virus glycoprotein complex gMgN has been implicated in assembly and release of fully
enveloped virus, although the precise role that it plays has not been elucidated. We report here that the
long predicted cytoplasmic tail of gM is not required for complex formation and that it interacts with the
cellular protein p32, which has been reported to be involved in nuclear egress of human cytomegalovirus
and herpes simplex virus. Although redistribution of p32 and colocalization with gM was not observed in
virus infected cells, knockdown of p32 expression by siRNA or lentivirus-delivered shRNA recapitulated
the phenotype of a virus lacking expression of gNgM. A proportion of virus released from cells sedi-
mented with characteristics of virus lacking an intact envelope and there was an increase in virus
trapped in nuclear condensed chromatin. The observations suggest the possibility that p32 may also be
involved in nuclear egress of Epstein–Barr virus.
& 2016 Elsevier Inc. All rights reserved.Introduction
The envelope proteins of herpesviruses play important roles at
several points in infection. They are critical to virus entry and to
assembly and egress. They inﬂuence virus spread and they can
modify the host innate and adaptive immune response. The
envelope of the oncogenic human gammaherpesvirus, Epstein–
Barr virus (EBV), contains eleven glycoprotein species including
three heterodimeric complexes, gHgL, BDLF2/BMRF2 and gMgN. In
all cases one member of the complex is dependent on the other for
trafﬁcking out of the endoplasmic reticulum (Yaswen et al., 1993;
Lake et al., 1998; Gore and Hutt-Fletcher, 2008). Two of the com-
plexes, gHgL and gMgN, are conserved herpesvirus glycoproteins.
The EBV gHgL complex, as in all herpesviruses, is required for
virus-cell fusion (Hutt-Fletcher, 2007). The roles of the conservedand Immunology, Louisiana
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her).
and Bioinformatics, Jaypee
olan, Himachal Pradesh 173
chool of Life Sciences, Sikkim
f Medicine, Imperial College
1PG, UK.gMgN complexes are more diverse. In many herpesviruses the
glycoproteins are classiﬁed as non-essential, though in general
they have been implicated in some way in assembly and egress
and spread and they all bear structural similarities. The gM part-
ners are multispan membrane proteins, whereas the gN homologs
are smaller type 1 integral membrane proteins.
Herpes simplex virus gM is important for the efﬁcient incor-
poration of gHgL into the virion membrane (Ren et al., 2012) and
although a gM-null virus has a only small reduction in replication
rate (MacLean et al., 1993; Browne et al., 2004), virus which lacks
both gM and the membrane associated tegument protein pUL11 is
signiﬁcantly impaired in secondary envelopment (Leege et al.,
2009). Deletion of the homologous proteins in the alpha-
herpesvirus pseudorabies virus results in a similar but even more
severe phenotype (Kopp et al., 2004). Defects in virus egress or cell
to cell spread are also found in equine herpesvirus 1 (Osterrieder
et al., 1996), varicella zoster virus (Yamagishi et al., 2008) and
equid herpesvirus 4 (Ziegler et al., 2005) lacking gM, and the gM
homologs of Marek's Disease virus (Tischer et al., 2002) and
murine gammaherpesvirus 68 (May et al., 2005) are essential for
production of virions. Perhaps the most extensively studied gMgN
complex, however, is that of the human cytomegalovirus (HCMV),
where gN and gM are not only both essential (Hobom et al., 2000;
Mach et al., 2005), but are also the most abundant glycoproteins in
the virion (Varnum et al., 2004). HCMV gN plays a critical role in
secondary envelopment (Mach et al., 2007) and the cytoplasmic
H. Changotra et al. / Virology 489 (2016) 223–232224tail of gM, which is essential for replication (Krzyzaniak et al.,
2007), interacts with the RabII effector protein FIP4 (Krzyzaniak et
al., 2009) and is important for transport of the gMgN complex to
the assembly compartment.
We previously made a recombinant EBV in which the gN open
reading frame was interrupted by a neomycin resistance cassette.
The virus was found to be phenotypically null for both gN and gM
(Lake and Hutt-Fletcher, 2000). Cells induced to make the
recombinant virus released fewer particles than cells making wild
type virus and they lysed more rapidly. Some virions accumulated
in condensed chromatin in the nucleus, few enveloped particles
were seen in the cytoplasm and the majority of virions that were
released lacked an intact envelope as judged by isopycnic sedi-
mentation. The few enveloped virions that were harvested were
impaired in infectivity at a step following fusion. We had no
explanation for the accumulation of virions in chromatin, however,
we speculated that, as had been suggested for pseudorabies virus
gM (Brack et al., 1999, 2000), where gM serves a redundant
function with gE/gI, the role for EBV gM might be in directing
capsids to the site of envelopment by recruiting capsid-associating
tegument proteins. The cytoplasmic tail of EBV gM, which is pre-
dicted to be 79 amino acids long, is highly charged and rich in
proline residues. We therefore here ﬁrst explored whether the 79
amino acids were important to formation of the gNgM complex
and second, whether, like the carboxy-terminal sequences of
HCMV gM, they mediated interactions with other cell or viral
proteins.Results
The cytoplasmic tail of gM is not required for its association with gN
Glycoprotein M is essential to the processing and transport of
the gMgN complex. To determine if complex formation requires
the predicted C-terminal cytoplasmic domain of gM, CV-1 cells
were infected with vaccinia virus expressing T7 polymerase,50-
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Fig. 1. Interaction of gN and truncated gM. SDS-PAGE and autoradiography of extracts o
pTM1 plasmids encoding HA-gM, gN, or HA-gMΔ79 as indicated, labeled with [3H]-leuc
with antibodies to HA. Arrows indicated the positions of gM and gN.transfected with pTM1gN and either pTM1-HA-gM or pTM1-HA-
gMΔ79, lacking the 79 amino acids carboxyterminal to the last
predicted transmembrane domain of gM, labeled biosynthetically
with [3H]leucine, lysed and immunoprecipitated with antibody to
HA or to gN. Both antibodies precipitated a complex of gN, which
runs as two bands of approximately 15 and 10 kDa, and either full
length or truncated gM (Fig. 1).The cytoplasmic tail of gM interacts with p32
Since the predicted long cytoplasmic domain of gM was not
required for formation of the complex with gN we sought to
determine whether it interacted with any other virus or cell pro-
teins. The C-terminal 79 amino acids of gM proved to be toxic to
yeast and were thus unsuitable for a yeast two-hybrid screen.
Instead they were cloned in frame for expression as a fusion
protein with GST. GST-gM and GST bound to glutathione-
Sepharose were added to lysates of Akata cells and Akata cells
that had been induced to make EBV. The cells had been bio-
synthetically labeled with [3H]leucine and the proteins that pre-
cipitated with the beads were analyzed by electrophoresis and
autoradiography. A protein with a mobility of approximately
32 kDa was uniquely pulled downwith GST-gM from both induced
and uninduced Akata cells (Fig. 2). The mobility of this protein was
almost exactly the same as the mobility of the GST-gM fusion
protein, which would complicate its mass spectroscopic analysis.
The same sequences of gM were therefore cloned for expression as
a larger fusion protein with MBP. MBP-gM, but not MBP alone,
pulled down a protein from EBV-negative Akata cells which had
the same mobility as that pulled down by GST-gM (Fig. 3). Since
the carboxyterminus of gM includes 9 proline residues and
therefore might be considered an intrinsically “sticky” protein we
also included as additional control a GST fusion with the amino-
terminal 169 residues of the BDLF2 protein, which are also cyto-
plasmic, and include 13 proline residues. The GST-BDLF2 fusion did
not interact with the 32 kDa protein.gM
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Fig. 2. Proteins pulled down by GST or GST-gM. SDS-PAGE and autoradiography of
extracts of induced (I) or uninduced (U) Akata cells labeled with [3H]-leucine and
pulled down with GST or GST-gM bound to glutathione-Sepharose.
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Fig. 3. Proteins pulled down by MBP or MBP-gM. SDS-PAGE and autoradiography of
extracts of uninduced Akata cells labeled with [3H]-leucine and pulled down with
MBP or MBP-gM bound to amylose resin.
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Fig. 4. Interaction of gM with p32. (A) Coomassie-stained SDS-PAGE analysis of
proteins pulled down by MBP or MBP-gM from uninduced Akata cell lysates.
MW¼molecular weight markers. Arrow indicates protein excised for analysis.
(B) Tryptic peptides (bold) identiﬁed by mass spectroscopy of the excised protein
which correspond to the sequence of p32/gC1-q-R. (C) Western blot analysis with
antibody to p32 of proteins pulled down from Akata cell lysate by MBP or MBP-gM.
H. Changotra et al. / Virology 489 (2016) 223–232 225To determine the identity of the 32 kDa protein, unlabeled EBV-
negative Akata cell lysates were precipitated with MBP-gM and
the proteins were visualized by staining with Coomassie Blue. The
region of the gel containing the protein (Fig. 4A) was excised and
analyzed by reverse phase HPLC–tandem mass spectrometry. A
search of the NCBInr human protein database identiﬁed four
tryptic peptides that corresponded to the sequence of p32/gC1qR(Fig. 4B), a multifunctional, multicompartmental protein. The
identity of the protein was conﬁrmed by Western blotting of
protein pulled down from EBV-negative Akata cells by MBP-gM
(Fig. 4C). To determine if the interaction could be recapitulated
with full-length gM, cells were nucleoporated with vectors
pCAGGS-HA-gM and pCAGGS-p32, lysed and either immunopre-
cipitated with antibody to HA and western blotted antibody to
p32, or vice versa. The interaction of gM and p32 could be seen by
both protocols (Fig. 5); an unrelated HA-tagged EBV protein, BFLF2,
did not interact with p32, serving as an additional control for
speciﬁcity. Despite the fact that our previous GST-pull downs
clearly indicated that endogenous p32 could interact with the gM
tail, we were, however, unable to immunoprecipitate detectable
levels of endogenous p32 with transfected gM. In addition, there
was no discernable colocalization of p32 and gM when the two
proteins were co-expressed in nucleoporated cells and the dis-
tribution of p32 was unchanged in induced Akata cells making
virus (Fig. 6).
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Fig. 5. Interaction of full-length gM with p32. Upper panels: SDS-PAGE and western blot analysis of lysates of AGS epithelial cells nuceloporated with vector pCAGGS (lanes
1 and 3), pCAGGS expressing full length HA-tagged gM and pCAGGS expressing p32 (lanes 2 and 4). Lysates in lanes 3 and 4 were either immunoprecipitated (IP) with
antibody to p32 and western blotted with antibody to HA, or immunoprecipitated with antibody to HA and western blotted with antibody to p32 as indicated. Lower panels:
SDS-PAGE and western blot analysis of lysates of AGS cells nucleoporated with pCAGGS-HA-BFLF2 and pCAGGS-p32. Lysates in lanes 3 were immunoprecipitated (IP) with
anti-HA. Lysates in lanes 2 and 3 were western blotted with antibody to p32; lysates in lane 1 were western blotted with anti-HA.
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virus released
Because we were only able to pull down endogenous p32 with
GST-gM we were concerned that the interaction was not biologi-
cally relevant. Since deletion of the gN gene and loss of the gMgN
complex had previously been shown to impair virus egress, we
therefore examined the effect of partially silencing p32 on virus
yields. Akata cells were transfected with siRNA to p32 or non-
targeting control siRNA, incubated for 96 h and then induced to
make virus. Twenty four h later virus was harvested from the
supernatant and the relative amounts of virus DNA in the cell and
the supernatant were measured by QPCR. Western blotting of cells
revealed a reduction in p32 expression by siRNA to a level of
approximately one third of the level in cells treated with non-
targeting siRNA (Fig. 7) and the viability of cells treated with either
siRNA was similar (not shown). In three separate knockdowns theaverage amount of virus DNA released from cells treated with
siRNAwas 53710% of the amount released from cells treated with
non-targeting siRNA. The virus that had been released after dele-
tion of the gN gene was in large part virus that lacked an envelope
(Lake and Hutt-Fletcher, 2000). Its ability to bind to CR2-positive
cells, with which the major virus attachment protein interacts, was
10% of that of wild type virus and its sedimentation rate increased.
The properties of the virus released from cells treated with siRNA
to p32 or non-targeting siRNA were therefore compared. Virus
harvested from cells treated with siRNA to p32 in two separate
knockdowns was reduced in its ability to bind to SVKCR2 cells by
37.6% and 38.9% respectively. This is much less than the impair-
ment of virus lacking the gNgM complex. However, we do not
know if we have reduced p32 completely in 66% percent of cells or
more than that in a subpopulation of cells, induction of virus
replication occurs only in around 50% of cells and the two popu-
lations are unlikely to overlap completely. We had previously
Fig. 6. Confocal images of cellular localization of p32 after nucleoporation or virus
induction. Top panel: cells were nucleoporated with pCAGGS-p32, pCAGGS-HA-gM,
pCAGGS-gN and stained with DAPI, antibody to p32 (red) and antibody to HA
(green). Bottom panel: Akata cells were induced to make virus and cells were
stained with DAPI, antibody to gB (red) and antibody to p32 (green).
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Fig. 7. Sedimentation analysis of virus produced by cells treated with siRNA to p32.
A. Western blot of virus-producing Akata cell lysates transfected with siRNA to p32
(lanes 1) or non-targeting siRNA (lanes 2) with antibody to p32 or tubulin as
indicated. B. Sedimentation proﬁles in 24–42% Nycodenz of virus produced from
cells transfected with non-targeting siRNA (upper panel) or siRNA targeting p32
(lower panel). Virus DNA in each fraction was measured by QPCR.
H. Changotra et al. / Virology 489 (2016) 223–232 227found that intact virus capable of binding to CR2 sediments pre-
dominantly in fractions with a refractive index of 1.36 whereas
virus unable to bind, because of a damaged or completely lost
envelope, sedimented in fractions with a refractive index greater
than 1.38. We now found that the sedimentation rate in a 24–42%
Nycodenz gradient of much of the virus released from cells treated
with siRNA to p32 also increased relative to virus released from
cells treated with non-targeting siRNA (Fig. 7).
In an attempt to establish stable clones of Akata that lacked p32
we transduced cells with a pool of three lentiviruses expressing
shRNA targeting p32 or lentiviruses expressing non-targeting
shRNA and selected the cells with puromycin. Clones were
screened by western blotting for p32 and p32 negative clones
were obtained. However, when the clones were expanded to
numbers that enabled virus production it was determined that all
had regained expression of p32. To complement the studies in
which p32 expression was knocked down with siRNA cells were
then transduced with the targeting and non-targeting lentiviruses
and selected for only 8 days on puromycin, to enrich for trans-
duced cells, before induction of virus. Thirty six hours after
induction virus was harvested, cells were analyzed by western
blotting to determine levels of expression of p32 and virus was
harvested for sedimentation analysis. The expression of p32 in
cells transduced with lentivirus targeting p32 was again reduced
to approximately one third of that in cells transduced with non-
targeting lentivirus and, again, the sedimentation proﬁle of the
virus released was consistent with a signiﬁcant proportion lacking
an intact envelope (Fig. 8). We also examined the induced andtransduced cells by electron microscopy (Fig. 9). In only 4 out of 60
virus positive cells transduced with non-targeting lentivirus, EBV
could be seen in condensed chromatin whereas nucleocapsids
were found in condensed chromatin in 13 out of 60 cells trans-
duced with lentivirus targeting p32.Discussion
Assembly and egress of EBV have not been as extensively stu-
died as have the same processes in several other herpesviruses,
largely due to difﬁculties in studying a virus that is not repro-
ducibly reactivated in a large majority of latently infected cells and
produces virus particles asynchronously, at less than robust levels,
over a period of several days. Most efforts have focused on
understanding capsid assembly (Henson et al., 2009; Wang et al.,
2011), which occurs at promyelocytic leukemia nuclear bodies
(Wang et al., 2015), and initial nuclear egress. Nuclear egress
requires the dimeric complex of BFRF1 and BFLF2 (Lake and Hutt-
Fletcher, 2004; Farina et al., 2005; Granato et al., 2008), homologs
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Fig. 8. Sedimentation proﬁle of virus produced by cells transduced with lentivirus
expressing shRNA to p32. A. Western blot of uninduced Akata cells (lane 1),
induced Akata cells (lane 2), induced Akata cells transduced with non-targeting
lentivirus (lane 3) or induced Akata cells transduced with lentivirus targeting p32
(lane 4). Blots were probed with antibodies to tubulin (upper bands) and p32
(lower bands). B. Sedimentation proﬁles in 24–42% Nycodenz of virus produced
from cells transduced with non-targeting lentivirus (upper panel) or lentivirus
targeting p32 (lower panel). Virus DNA in each fraction was measured by QPCR.
H. Changotra et al. / Virology 489 (2016) 223–232228of the nuclear egress complex proteins of alpha and beta-
herpesviruses, which are critical for budding into the perinuclear
space, and the viral kinase BGLF4 (Gershburg et al., 2007). Much
less is known about movement of EBV into, through and out of the
cytoplasm, although the assumption is generally made that it
follows an deenvelopment, reenvelopment pathway similar in
outline to that of other herpesviruses (Johnson and Baines, 2011).
Our previous work with the gN-null recombinant virus had
implicated gNgM in the process, possibly at the stage of secondary
envelopment (Lake and Hutt-Fletcher, 2000) and we had specu-
lated that the role for EBV gM might be in directing capsids to the
site of envelopment by recruiting capsid-associating tegument
proteins. Our expectation therefore was that the predicted cyto-
plasmic tail of gM, which, like that of HCMV (Mach et al., 2005),
was not required for formation of the gNgM complex, would
interact with one or more of the EBV tegument proteins. It wasthus a surprise that the protein we identiﬁed as binding to the 79
carboxyterminal residues of gM, was p32.
Human p32 is also known as gC1q-R/p33, a receptor for the
complement component C1q, p32/TAP and SF2-associated p32. It
is an enigmatic, evolutionarily conserved, widely expressed
molecule that has been variously described as a mitochondrial
matrix protein (Jiang et al., 1999) and a multi-compartment pro-
tein expressed both intracellularly and on the cell surface (Gheb-
rehiwet et al., 2001). It has been shown to recognize diverse
ligands, both microbial, cellular and of course those found in
plasma. It has been reported to interact with a confusingly large
number of disparate virus proteins, including HIV-1 Tat and Rev,
EBV EBNA1, ORF P of herpes simplex virus, rubella capsid protein
and core protein V of adenovirus (reviewed in (Ghebrehiwet and
Peerschke, 2004)) and has also been described as a general reg-
ulator of protein kinase C location and function (Robles-Flores et
al., 2002). Of particular interest, it has recently been implicated in
nuclear egress of human cytomegalovirus (Marschall et al., 2005;
Milbradt et al., 2007) and herpes simplex virus (Wang et al., 2014;
Liu et al., 2015). The human cytomegalovirus protein kinase,
pUL97, interacts with p32 and accumulates at the nuclear mem-
brane. The model is then that the cell protein acts as an adapter for
recruitment of proteins to the nuclear lamin where it interacts
with the lamin B receptor. Recruitment of virus and cellular pro-
tein kinases leads to the disintegration of nuclear lamina which is
required for virus egress.
The phenotype seen here for EBV is at least partially consistent
with the observations made for alpha and beta herpesviruses. An
EBV protein, gM, which has been implicated in egress, can interact
with p32. Unlike the observations made with herpes simplex virus
infected cells (Wang et al., 2014; Liu et al., 2015), however, we
were unable to detect any change in the punctate location of
endogenous p32 in cells that had been induced to make virus and
saw no colocalization of p32 and gM when the gNgM complex was
expressed together with exogenous p32. This raised concern as to
the biologic signiﬁcance of the ﬁnding. In support of its relevance,
the effects of reducing expression levels of p32 did, nevertheless,
recapitulate ﬁndings made with the genotypically gN-null virus
that we had previously made. This virus, phenotypically null for
the entire gNgM complex, produced extracellular particles which
sedimented in isopycnic gradients at rates characteristic of those
either lacking an envelope or being incompletely enveloped. The
same was true of virus particles made in cells partially knocked
down for p32 expression by either siRNA or lentivirus expressed
shRNA. We cannot know in how many cells the levels of p32 are
reduced, which confounds interpretation of the electron micro-
scopy done. However, it would appear that the phenotype of the
gN-null virus, which in part remained associated with condensed
chromatin, was also partially reproduced by p32 knockdown.
The original assumption that the EBV gNgM complex was
involved in secondary envelopment rather than nuclear egress was
based on visualization of unenveloped capsids in the cytoplasm of
cells making the gN-null virus. In view of the current ﬁndings and
those made with alpha and betaherpesviruses, however, it seems
possible that the primary defect may actually have been in nuclear
egress and that the cytoplasmic particles represented some kind of
nuclear breakdown, even though none was obvious (Lake and
Hutt-Fletcher, 2000). At this point it is premature to speculate as
to whether p32 is part of an EBV nuclear egress complex, but the
function conservation throughout the herpesvirus subfamilies of
other virus proteins involved in egress, such as the homologs of
BFRF1, BFLF2 and BGLF4, suggests that the possibility should be
explored further.
mn005mn005
Fig. 9. Electron micrographs of induced Akata cells which had been transduced with lentivirus targeting p32 (left panel) or non-targeting lentivirus (right panel). Cells were
harvested after being induced for 24 h.
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Cells, virus and antibodies
Akata B cells, Burkitt lymphoma-derived cells that carry and
can be induced to make EBV (Takada, 1984), and EBV negative-
Akata B cells were grown in RPMI 1640 (Sigma). CV-1 monkey
kidney cells were grown in Dulbecco's modiﬁed Eagle’s medium,
AGS gastric carcinoma cells (American Type Culture Collection)
were grown in F-12 Nutrient Mixture (Gibco) and SVKCR2 cells, an
SV40-transformed keratinocyte cell line engineered to express CR2
(Li et al., 1992) were grown in Joklik’s modiﬁed Eagle's medium
supplemented with 10-ng/ml cholera toxin (Sigma) and 10% calf
serum (Hyclone). All other media were supplemented with 10%
heat-inactivated fetal bovine serum (Gibco). Akata cells at a con-
centration of 106/ml were induced to make virus by incubation
with 100 mg/ml goat anti-human globulin (MP Biomedics). Vacci-
nia virus expressing T7 polymerase was made as described (Lake
et al., 1998). GIPZ lentiviruses expressing shRNA targeting p32
(V2LHS_112642, V3LHS_379794 and V3LHS_379796) and non-
targeting lentiviruses were obtained from ThermoFisher and
used to transduce Akata cells according to the manufacturer’s
instructions. Antibodies used were monoclonal antibodies 72A1 to
gp350 (Hoffman et al., 1980), CL55 to gB, sc23885 to p32 (Santa
Cruz Biotechnology), 16B.12 to HA (Covance) and to tubulin alpha
Ab-2 (DMIA) (NeoMarkers) and rabbit polyclonal antibodies
sc48795 to p32 (Santa Cruz Biotechmology), HA.11 to HA (Cov-
ance) and to peptides corresponding to residues 44–69 of gN (Lake
and Hutt-Fletcher, 2004). Secondary antibodies included goat anti-
mouse IgG1 conjugated to AlexaFluor 488, goat anti-IgG2a con-
jugated to AlexaFluor 594, goat anti-mouse IgG conjugated to
AlexaFluor 488 and goat anti-rabbot conjugated to AlexaFluor 594
(Invitrogen). All non-commercial antibodies were puriﬁed by
afﬁnity chromatography on Protein A-Sepharose 4B (Sigma).
Expression plasmids
The predicted cytoplasmic tail of gM, residues 327–405, was
cloned for expression in bacteria as a fusion protein with glu-
tathione S-transferase (GST-gM) and as a fusion protein with
maltose-binding protein (MBP-gM) using vectors pGEX-5X-3 (GE
Healthcare) and pMAL-c4 (New England Biolabs) respectively. To
make pGEX-gM, sequences were ampliﬁed from Akata virus DNA
with forward primer 50-CATTAGGATCCTCAAAA GCATGCGCCAG-30
which included a BamHI site and reverse primer 50-CAATACTC
GAGTTAGGGGAAGATCTCCTCC-30, which included an XhoI site andinserted into pGEX-5X-3 cut with BamHI and XhoI. To make
pMAL-c4-gM sequences were ampliﬁed with forward primer 50-
CATTAGGATCCAAAAGCATGCGCCA-30 which included a BamHI site
and reverse primer 50-TGAGAAGCTTTTAGGGGAAGATCTCCTC-30
which included a HindIII site and inserted into pMAL-c4x vector
cut with BamHI and HindIII. The 169 residue cytoplasmic tail of
BDLF2 was also cloned for expression as a fusion protein with
glutathione S-transferase (GST-BDLF2) as described (Gore and
Hutt-Fletcher, 2008). For expression in mammalian cells, genes
were either cloned into the pTM1 vector under control of the T7
promoter (Moss et al., 1990), or cloned into the pCAGGS/MCS
vector (a gift of Martin Muggeridge, LSUHSC) under control of the
β-actin promoter in cooperation with the HCMV-IE enhancer
(Niwa et al., 1991). Plasmids pTM1 gM and pTM1 gN were pre-
viously described (Lake et al., 1998). To make pTM1-HA-gM, gM
sequences were ampliﬁed from pTM1-gM with forward primer 50-
GGCCTCAGCATATGAAGTCCTCCAA-30 containing an NdeI site and
reverse primer 50-GGCGGATCCTTAGGGGAAGACT-30 which con-
tained a BamH1 site. The ampliﬁed fragment was cloned into
pGADT7 cut with NdeI and BamHI to make pGADT7-HA-gM. An
NcoI/BamHI fragment containing HA-gM was then cloned back
into pTM1. To make pCAGGS-HA-gM an NcoI/XhoI fragment from
pTM1-HA-gM, in which the NcoI site had been blunted, was
cloned into pCAGGS cut with SmaI and XhoI. To make pTM1-
HAgMΔ79gM sequences were ampliﬁed from pTM1-HAgM with
forward primer 50-GGCCTCAGCATATGAAGTCCTCCAA-30 and
reverse primer 50-GATCTCGAGTTAGAAAATCCGGCATATCC-30. The
ampliﬁed fragment was cut with NdeI and XhoI and cloned into
pTM1-HAgM cut with the same enzymes. To make pCAGGS-p32,
cDNA was made from RNA extracted from Akata cells and ampli-
ﬁed with forward primer 5’-CAGTGAATTCGCCACCATGCTGC-
CTCTGCTGCGC-3’ which included an EcoRI site and reverse primer,
50-TTACAGATCTCTACTGGCTCTTGACAAAACTCTTG-30 which inclu-
ded a BglII site and was inserted into pCAGGS which had been cut
with EcoRI and BglII. Plasmid pCAGGS-HA-BFLF2 was recloned
from the previously described pTM1-HA-BFLF2 (Lake and Hutt-
Fletcher, 2004). All PCR ampliﬁcations were done with Pfx (Invi-
trogen) and constructs checked by sequencing.
Expression of proteins in mammalian cells
The pCAGGS vectors were nucleoporated into cells (see below).
For expression in from pTMI vectors cells were infected with
vaccinia virus and transfected with plasmid using Lipofectamine
(Gibco) as previously described (Lake et al., 1998).
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NEB5-α cells (New England Biolabs) carrying pGEX-gM or
pGEX-5X-3 were induced with 0.15 mM isopropyl-β-D-thioga-
lactopyranoside when the OD600 of the culture reached 0.5 and
were grown for 3 h more at 37 °C before harvesting by cen-
trifugation. The bacteria were resuspended in phosphate buffered
saline (PBS) containing 1% Triton X-100 (Sigma) and Complete
Mini EDTA-free protease inhibitors (Roche). After sonication cel-
lular debris was removed by centrifugation and GST and GST-gM
were puriﬁed from the lysates on glutathione-Sepharose (Amer-
sham) following the manufacturer’s instructions. Arctic Express
RIL cells (Stratagene) carrying pMAL-c4-gM or pMAL-c4 were
induced with 0.15 mM isopropyl-β-D-thiogalactopyranoside when
the OD600 of the culture reached 0.5 and were grown for 24 h
more at 13 °C. Cells were harvested by centrifugation and resus-
pended in lysis buffer (20 mM Tris–HCl [pH 7.4], 200 mM NaCl
1 mM EDTA) containing Complete Mini EDTA-free protease inhi-
bitors. Lysozyme was added (1 mg/ml), the lysates were incubated
at room temperature for 15 min, sonicated, centrifuged to remove
cell debris and incubated with amylose resin (New England Bio-
labs) to purify MBP or MBP-gM according to the manufacturer’s
protocol.
Radiolabeling and precipitation
Two million Akata cells were induced to make EBV by induc-
tion with 100 mg goat (Fab’)2 anti-human immunoglobulin G (MP
Biomedicals). Four h later cells were suspended in leucine-free
medium (Gibco) for 2 h and then labeled for 24 h with 200 mg [3H]
leucine (100–150 Ci/mmol; Perkin Elmer). Two million EBV-
negative Akata cells were suspended in leucine-free medium for
2 h and labeled for 24 h with 200 mg [3H]leucine. Labeled cells
were solubilized in radioimmunoprecipitation buffer, (RIPA;
50 mM Tris–HCl [pH 7.2], 0.15 M NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.1 mM phe-
nylmethylsulfonyl ﬂuoride, 100 U of aprotinin per ml). Lysates
were incubated overnight at 4 °C with 100 μg GST or GST-gM
bound to glutathione-Sepharose, or 100 mg MBP or MBP-gM
bound to amylose resin. Beads were washed 10 times with RIPA
and boiled for 3 min in sample buffer containing β-
mercaptoethanol. Dissociated proteins were analyzed by SDS-
polyacrylamide electrophoresis in either 12% polyacryamide
cross-linked with bis-acrylamide, followed by ﬂuorography or in
9–18% gradient gels.
Mass spectrometry
For identiﬁcation of proteins interacting with MBP-gM, Akata
cells (1.5107) were lysed in RIPA. Lysates were incubated either
MBP or MBP-gM bound to amylose beads, beads were washed 10
times with RIPA and boiled for 3 min. Dissociated proteins were
separated by electrophoresis in a 12.5% Criterion Tris–HCl poly-
acrylamide gel (BioRad). The gel was stained with coomassie blue
and slices of gel containing the protein of interest were cut out and
stored in 0.1% formic acid until analyzed by mass spectrometry.
Gel slices were reduced, alkylated and digested with trypsin. The
peptide extracts were analyzed in triplicate on a LTQ FT mass
spectrometer (Therno Fisher Scientiﬁc) coupled with a 2D NanoLC
(Eksigent Technologies, California, USA). In each run, the sample
was injected with 1D pump to a trap-column (100 mm ID fused
silica, packed in-house with 3 cm of 100 Å, 5 m, Magic C18 parti-
cles, Michrom Bioresources), and washed with 0.1% formic acid for
15 min at 0.5 ml/min. Before elution of the peptides the trap-
column was connected to an analytical column (75 mm ID fused
silica, packed in-house with 12 cm of 100 Å, 5 m, Magic C18particles, Michrom Bioresources) that was mounted on the elec-
trospray stage of a LTQ FT mass spectrometer (ThermoFinnigan).
The mobile phase A and B in the 2D pump were 0.1% formic acid,
and 0.1% formic acid in acetonitrile. The gradient proﬁle was as
follows: 0–5 min, 5–15% B; 5–60 min, 15-40% B; 60–70 min, 40% B;
70–75 min, 40–75% B; 75–83 min 75% B. At the end the column
was washed with 90% B. The ﬂow rate was maintained at 300 nl/
min and using an electrospray voltage of 1.9 kV with the ion
transfer temperature set to 250 °C. The mass spectrometer was
controlled by the Xcalibur software to perform continuously mass
scan analysis on the FT in the range of 400–1900m/z at 50,000
resolution, followed by MSMS scans on the ion trap of the six most
intense ions, with a dynamic exclusion of two repeat scans of the
same ion, 60 s repeat duration and 90 s exclusion duration. Nor-
malized collision energy for MS/MS was set to 35%. Isolation with
was 2. For data analysis all MSMS scans were searched using
Proteome Discoverer (version 1.4,ThermoFisher Scientiﬁc) running
Sequest as the search algorithm. Database search was conducted
against a human protein database derived from the NIBInr repo-
sitory (as on 08 15, 2015), using trypsin cleavage speciﬁcity and a
maximum of 2 missed cleavages. The following variable mod-
iﬁcations were selected: pyroglutamination from Q (N-terminal),
oxidation of M and deamidation of N, Q; carboxymethylation of C
was selected as a ﬁxed modiﬁcation, a maximum of 3 modiﬁca-
tions/peptide were allowed. Estimation of false positive rate (FDR)
was conducted by searching all spectra against a decoy database
consisting of the inverted sequences of all proteins in the original
(direct) database. A minimum Xcorr score 0f 1.8, 2.5 and 3.8 for
ions with 1, 2, and 3 charges, respectively, and a peptide score
larger than 0.1 was required for tandem MS selection. For protein
identiﬁcation, a FDRr0.1 was deﬁned and a minimum of two
unique peptides per protein was required. Amino acid sequence
assignments of all peptides of interest were subsequently inspec-
ted manually.
Western blotting
Western blotting of electrophoresed proteins was done as
previously described (Molesworth et al., 2000). Membranes were
reacted with appropriate concentrations of primary and horse-
radish peroxidase-conjugated secondary antibodies (Amersham),
were washed several times and were developed with ECL plus
western blotting detection system (GE Healthcare) according to
the manufacturer's instructions.
Virus binding
Virus concentrations were adjusted to contain equal amounts
of encapsidated EBV DNA after analysis by Quantitative Real Time-
PCR (QPCR). Virus binding was measured by incubating virus with
106 SVKCR2 cells for 2 h at 4 °C, after which cells were washed
3 times with PBS and scraped off into ice cold versene (Invitrogen).
The cells were pelleted by centrifugation and DNA was isolated
with QIAamp DNA Blood Mini Kits (QIAGEN Sciences) for deter-
mination of the amount of virus DNA bound by QPCR.
Quantitative Real Time-PCR (QPCR)
Genomic DNA from cells was isolated with QIAamp DNA Blood
Mini Kit (QIAGEN Sciences). For isolation of DNA from super-
natants (passed through 0.8 μm ﬁlter), these were ﬁrst digested
with DNase I (2 U/ 20 ml of supernatant) for 1 h at 37 °C followed
by heat inactivation of the enzyme (65 °C for 15 min) after addi-
tion of stop solution. Supernatants were diluted (1:10) with water
containing proteinase K (1 mg/ml), incubated at 56 °C for 2 h and
boiled for 2 min to inactivate the enzyme. The solution was further
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(Turk et al., 2006). Brieﬂy A 76-bp region of the EBV EBNA1 gene in
the single copy BamHI K fragment was ampliﬁed with primers 50-
GGATGCGATTAAGGACCTTGTT-30 and 50-CGTCAAAGCTGCACA-
CAGTCA-30, base coordinates 109677 and 109753, respectively
(NCBI GenBank accession number VO1555) At the same time a
101-bp DNA sequence of the human C-reactive protein (CRP) gene
was ampliﬁed with primers 5'-CTTGACCAGCCTCTCTCATGC-30 and
50-TGCAGTCT TAGACCCCACCC-30, base coordinates 132705 and
132605, respectively (accession no. AL445528). Ampliﬁcations
were done with the TaqMan Fluorogenic System (PE Applied
Biosystems). The EBNA1 probe (50-CAAAGCCCGCTCCTACCTGCAA-
TATCA-30, base coordinate 109703) was labeled with 6-
carboxyﬂuorescein and the CPR probe (50-TTTGGCCAGA-
CAGGTAAGGGCCACC-30, base coordinate 132682) was labeled with
VIC (PE Applied Biosystems). Reactions were performed in a 50 ml
volume with TaqMan Universal Master Mix (PE Applied Biosys-
tems), 300 nM primers, 200 nmol/liter probe, and 400 or 200 ng of
DNA. Ampliﬁcation consisted of 2 min at 50 °C, 10 min at 95 °C,
and 50 two-step cycles of 15 s at 95 °C and 60 s at 60 °C. Each
sample was run in duplicate, together with multiple template-
negative controls. Serial dilutions of IB4 DNA, a Burkitt's lym-
phoma cell line containing ﬁve copies of EBV per cell, served as the
standard. The EBV copy number per sample was normalized to the
amount of CRP DNA representing the actual amount of ampliﬁable
cellular DNA in each sample.
Nucleofection
AGS cells were nucleoporated with pCAGGS, pCAGGS-HA-gM
or pCAGGS-p32 proteins following the manufacturer's protocol
(Amaxa). Brieﬂy, 8 mg of DNA was nucleoporated per 5106 cells
using Kit V and program T-20. Nucleofected cells were incubated
at 37 °C in growth media for 48 h before further analysis. For
knock down of RNA, 2 μM siRNA (Dharmacon) to p32 (L-011225-
01) or a non-targeting control (D-001810-10) were nucleoporated
into 106 EBV positive Akata cells using Kit V and program G-16.
Cells were incubated at 37 °C for 96 h before further analysis or
processing.
Immunoprecipitation
For immunoprecipitation, AGS cells were washed with PBS,
collected in versene (Invitrogen), washed with PBS again and then
lysed in RIPA. Lysates (500 μg at 1 μg/μl concentration) were pre-
cleared with either protein A- (Sigma) or protein G-agarose
(Pierce) beads for 30 min at 4 °C and then appropriate antibodies
(5-8 μg) were added for immunoprecipitation at 4 °C for 2 h.
Lysates were reincubated for 1 h at 4 °C after addition of protein A-
or protein G-agarose beads. Pelleted beads were washed twice
with RIPA and 3 times with PBS. Immunoprecipitated proteins
were dissociated by boiling for 3 min in sample buffer containing
β-mercaptoethanol (samples were instead held at 56 °C for 30 min
when full length gM was used) and analyzed by SDS-
polyacrylamide electrophoresis in 12% polyacryamide cross-
linked with bis-acrylamide.
Sedimentation analysis of virus
Virus was harvested from the supernatant of Akata cells that
had been nucleoporated with siRNA incubated for 96 h and
induced for 24 h or transduced with lentivirus, selected on pur-
omycin for 8 days, induced for 36 h. Five hundred ml of the virus
were loaded onto a 24 to 42% continuous gradient of Nycodenz
(Sigma) in 1 mM potassium phosphate containing 0.01% bacitracin
made, as previously described (Lake and Hutt-Fletcher, 2000), bylayering 1 ml of 42, 40, 38, 36, 34, 32, 30, 28, 26 and 24% Nycodenz
in a centrifuge tube and allowing the steps to diffuse overnight at
4 °C. The gradient was centrifuged in a Beckman SW41 Ti rotor at
70,000 g for 2 h at 4 °C and 500 ml fractions were harvested from
the top. The refractive index of each fraction was measured and
the amount of virus in each was determined by QPCR.
Electron microscopy
Ten million cells were pelleted at 350 g and washed with
cacodylate buffer (01.5 M sodium cacodylate, 2 mM calcium
chloride) at 4 °C. Cells were ﬁxed overnight at 4 °C in cacodylate
buffer containing 4% glutaraldehyde, washed 3 times in buffer
alone, transferred to a microcentrifuge tube, pelleted at 250 g
and resuspended in in 50 ml of cacodylate buffer containing 10%
gelatin prewarmed to 37 °C. Cells were pelleted at 250 g for 2 min
and put on ice. Each gelatin plug was cut into 1mm cubes which
were rinsed, postﬁxed for 1 h with osmium tetroxide, rinsed,
dehydrated and embedded in Araldite for sectioning.Acknowledgments
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